Transamerica Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Transamerica Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.9K	Sell	51 -18	-26%	-$12.3K	﹤0.01%	777
2026 Q1	$53.4K	Buy	69 +21	+44%	+$16.1K	﹤0.01%	641
2025 Q4	$37.1K	Buy	48 +38	+380%	+$25.8K	﹤0.01%	596
2025 Q3	$5.62K	Buy	+10	New	+$5.65K	﹤0.01%	843
2023 Q4	–	Sell	-3	Closed	-$3K	–	650
2023 Q3	$3K	Sell	3 -1	-25%	-$786	﹤0.01%	379
2023 Q2	$3K	Hold	4	–	–	﹤0.01%	349
2023 Q1	$4K	Hold	4	–	–	﹤0.01%	343
2022 Q4	$3K	Sell	4 -1	-20%	-$738	﹤0.01%	366
2022 Q3	$3K	Hold	5	–	–	﹤0.01%	363
2022 Q2	$3K	Buy	+5	New	+$3.25K	﹤0.01%	376
2021 Q3	–	Sell	-1	Closed	-$1K	–	184
2021 Q2	$1K	Buy	+1	New	+$507	0.02%	173

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Transamerica Financial Advisors's REGN Position: Q2 2026 in Review

Transamerica Financial Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 26% in Q2 2026, selling an estimated $12.3K and leaving 51 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #777.

Transamerica Financial Advisors first reported a position in REGN in Q2 2021 and has held it in 11 quarters since. The position peaked at $53.4K in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Transamerica Financial Advisors held 51 shares of Regeneron Pharmaceuticals worth $31.9K as of Q2 2026.
Transamerica Financial Advisors sold 18 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $12.3K.
Regeneron Pharmaceuticals made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #777 holding.
Transamerica Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
Transamerica Financial Advisors's Regeneron Pharmaceuticals position peaked at $53.4K in Q1 2026.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.